The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re: Partner Company

7 Nov 2006 10:24

Amphion Innovations PLC07 November 2006 Amphion Innovations Partner Company Durham Scientific Crystals Closes £875,000 Financing London, UK - 7 November 2006 - Amphion Innovations plc today announces that itsPartner Company, Durham Scientific Crystals Ltd. (DSC), a Durham Universityspin-out developing state-of-the-art semiconductor materials for the medicalimaging and security imaging markets, has raised an initial £875,000 at £2 pershare for the first close of a larger Series F financing. Amphion now owns 26.3%of Durham Scientific Crystals which is now valued at £8.3m post money. DSC has developed a breakthrough technology that is significant in thetransition from analogue to digital x-ray imaging. The Company hascommercialised the use of materials based on cadmium telluride, the premierchoice for use as digital detectors of x-rays and gamma rays, and will allow forsignificantly improved imaging in markets such as airport security and medicalimaging. Cadmium telluride materials are currently too expensive and too difficult toproduce to be used in large scale commercial applications. DSC, however, hasdeveloped a breakthrough production method to produce these crystals from avapour phase, rather than the conventional liquid based techniques, enabling thecrystals to be produced at an attractive cost and quality enabling their largescale commercial use in the future. The transformation to digital x-ray scanners in security imaging will be asignificant improvement as the technology will allow much faster screening anddirect 'fingerprinting' of dangerous materials such as liquid bombs and plasticexplosive, which are currently hard to distinguish from other plastics. In medical imaging, cadmium telluride will offer significant advantages over thecurrent materials including greater sensitivity to x-rays to enable fasterimaging and lower dosing, and will increase the ability to understand diseases,such as Alzheimer's and Cancer, and detect them in their early stages, The capital raised in this latest round of financing will support continuedresearch and development, staffing and overhead expenses. DSC is also workingwith non-commercial partners to optimise its crystals with electrode technologythat makes it easier to integrate them into the electronic infrastructure ofscanners. Richard C.E. Morgan, Chief Executive Officer of Amphion, said: "Due to the recent security issues in our airports, and the continued desire todiagnose and treat diseases earlier, there is a large growing need for faster,more effective and clearer digital imaging. We believe that DSC has thetechnology to meet these needs and this financing signifies that our investorsand partners see DSC as a company poised for tremendous growth and value thetechnology and recognise its prospects." Dr Arnab Basu, Chief Executive Officer of Durham Scientific Crystals, said: "We are excited by the response of the investment community and these funds willallow us to accelerate our R&D as we further continue to commercialise ourproducts to significantly improve imaging in the security and medical markets." For further information please contact: Amphion Innovations plcJosh Berkman, Media Relations +1 (646) 747-7158 Financial Dynamics +44 207 269 7169Ben AtwellJohn Gilbert About Amphion Innovations plc Amphion Innovations plc is listed on the AIM Exchange in London under the symbolAMP. Amphion's business is the formation, financing, management and developmentof life sciences and technology companies, working in partnership withcorporations, governments, universities and entrepreneurs seeking tocommercialize their intellectual property. Durham Scientific Crystals, Ltd. Durham Scientific Crystals, Ltd. is a research and development company, whichwas spun-out from the Physics Department of the University of Durham. Thecompany was formed in April 2003 and has been actively involved in the researchand development of semiconductor materials, in conjunction with the Universityresearch labs. DSC's technological expertise is a result of over three decadesof semiconductor research at the University of Durham. DSC is located in Sedgefield, County Durham, England and is developingnext-generation proprietary products and processes based around keysemiconductor optoelectronic materials used in medical and securityapplications. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
31st Dec 20191:15 pmRNSAmphion Innovations
31st Dec 201912:36 pmRNSCancellation of trading on AIM
20th Nov 20197:00 amRNSDirectors' Dealings and Business Update
18th Oct 20197:00 amRNSSettlement of loan facility
11th Oct 20197:01 amRNSPolarean notes statement from Amphion Innovations
11th Oct 20197:00 amRNSSale of Partner Company Shares
3rd Oct 20197:00 amRNSSale of Partner Company Shares
25th Sep 20197:00 amRNSAmended Terms on Loan Facility
10th Sep 20194:56 pmRNSSale of Partner Company Shares
9th Aug 20194:14 pmRNSStatement on Amphion Innovations
9th Aug 20194:14 pmRNSDirectorate Change
9th Aug 20193:51 pmRNSSale of Partner Company Shares
1st Jul 20197:30 amRNSSuspension - Amphion Innovations Plc
27th Jun 20193:00 pmRNSAnnual Report and Accounts Update
14th Jun 20199:04 amRNSHolding(s) in Company
12th Jun 20197:00 amRNSLoan facility update
31st May 201910:28 amRNSHolding(s) in Company
20th May 20196:14 pmRNSHolding(s) in Company
1st Apr 20194:40 pmRNSSecond Price Monitoring Extn
1st Apr 20194:35 pmRNSPrice Monitoring Extension
1st Apr 20197:00 amRNSUpdate on Loan Facility
20th Mar 20197:00 amRNSHolding(s) in Company
19th Mar 20192:33 pmRNSSale of Partner Company Shares
18th Mar 20192:00 pmRNSPrice Monitoring Extension
15th Mar 20197:01 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSSale of Partner Company Shares
11th Mar 20194:41 pmRNSAmended Terms on Loan Facility
26th Feb 20197:00 amRNSConvertible Promissory Note Extended
14th Feb 20198:00 amRNSStatement re. Motif Bio plc
7th Feb 20199:40 amRNSStmnt re Share Price Movement
1st Feb 20197:00 amRNSAppointment of Joint Broker
21st Jan 20197:00 amRNSWellGen Finalises License Agreement
11th Dec 20187:05 amRNSInvestment in Polarean & Loan Facility Repayment
16th Oct 20187:00 amRNSExtended Repayment and Draw Down on Loan Facility
28th Sep 20187:00 amRNSHalf-year Report
5th Sep 20187:00 amRNSBoard Change
23rd Aug 20183:20 pmRNSPolarean update
21st Aug 20187:15 amRNSMotif Bio notes statement from Amphion Innovations
21st Aug 20187:00 amRNSSale of Partner Company Shares
1st Aug 20184:47 pmRNSResult of AGM
29th Jun 20187:00 amRNSDirectorate Change
26th Jun 20187:00 amRNSFinal Results
23rd May 20187:00 amRNSMotif Bio notes statement from Amphion Innovations
23rd May 20187:00 amRNSSale of Partner Company Shares
20th Apr 20187:00 amRNSDirectorate Change
29th Mar 20187:00 amRNSAIM Admission & First Day of Dealings
29th Mar 20187:00 amRNSUpdate on Polarean Imaging IPO
26th Mar 20187:31 amRNSUpdate on Polarean Imaging proposed AIM IPO
2nd Mar 20187:00 amRNSConvertible promissory note extended to December
10th Jan 20185:09 pmRNSDirector dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.